Navigation Links
M. D. Anderson Cancer Center Researchers to Present CTCE-9908 Data,at the AACR Annual Meeting

y financing, reliance on subcontractors and key personnel and other risks detailed from time-to-time in the Company's public disclosure documents and other filings with the U.S. Securities and Exchange Commission and Canadian securities regulatory authorities. Forward-looking statements are made as of the date hereof, and the Company disclaims any intention and has no obligation or responsibility, except as required by law, to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.

CONTACT: Chemokine Therapeutics Corp., Mr. Don Evans, Director of Public Relations, Phone: (604) 822-0305, or 1-888-822-0305, Fax: (604) 822-0302, E-mail: , Internet: www.chemokine.net; Equicom Group, Joanna Longo, Investor Relations, Phone: (416) 815-0700 ext. 233, Fax: (416) 815-0080, E-mail: devans@chemokine.net jlongo@equicomgroup.com

CONTACT: Chemokine Therapeutics Corp., Mr. Don Evans, Director of PublicRelations, Phone: (604) 822-0305, or 1-888-822-0305, Fax: (604) 822-0302,E-mail: , Internet: www.chemokine.net; Equicom Group,Joanna Longo, Investor Relations, Phone: (416) 815-0700 ext. 233, Fax:(416) 815-0080, E-mail: devans@chemokine.net jlongo@equicomgroup.com

Ticker Symbol: (Toronto:CTI.),(NASDAQ-OTCBB:CHKT)

Terms and conditions of use apply
Copyright © 2007 PR Newswire Association LLC. All rights reserved.
A United Business Media Company


'"/>




Page: 1 2 3 4

Related medicine technology :

1. Dasatinib Shows High Early Response Rate as First Treatment for Chronic Myelogenous Leukemia, M. D. Anderson Researchers Report
2. Breast Cancer and HER-2/neu: Diagnostic Tools for Targeted Therapy
3. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
4. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
5. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
6. Protox Announces Positive Clinical Data from Prostate Cancer Study
7. Gene Therapy Eradicates Pancreatic Cancer in Preclinical Trial Targeting Systems Success in Mouse Model Reported in Cancer Cell
8. MediGene Announces Cancer-Fighting Virus Shows Promise in Early Clinical Trial
9. Response Genetics Announces Publication of a Phase III Clinical Trial Demonstrating That Low Levels of ERCC-1 Help to Predict Likelihood of Response to Cisplatin-Based Therapy in Lung Cancer
10. Study Shows Ixabepilone Demonstrated Clear Activity in Patients with Metastatic Breast Cancer Resistant to Anthracycline, Taxane, and Capecitabine
11. Peer Reviewed Journal Article Indicates Repros Proellex Exhibits Potential for New Approach to the Treatment and Prevention of Breast Cancer
Post Your Comments:
(Date:8/19/2014)... , Aug. 19, 2014  As power ... the country, Bernstein Liebhard LLP notes that women ... choose between a number of options that do ... surgical instrument. According to a report published by ... , these options include a mini-laparotomy and vaginal ...
(Date:8/19/2014)... 19, 2014 Research and Markets has ... of Material, by Technology, by Application & by Region- Global ... The demand for membranes is estimated to ... market to $29.31 billion Membrane technology was first ... as water filtration and kidney dialysis. In modern times, membranes ...
(Date:8/19/2014)... Avizia, Inc., a leading provider of cutting-edge ... equity financing round led by NextGen Angels along with ... will be used to continue to fuel the rapidly ... Edward Kennedy , CEO and president of Tollgrade ... Leonard Kurtzman , CFO of newBrandAnalytics, who joined the ...
Breaking Medicine Technology:As Morcellator Lawsuits Mount, Bernstein Liebhard LLP Notes Report Detailing Alternatives to Uterine Morcellation 2As Morcellator Lawsuits Mount, Bernstein Liebhard LLP Notes Report Detailing Alternatives to Uterine Morcellation 3Global Membranes (MF, RO, UF, Gas Separation, Dialysis, NF) Market - Forecasts to 2019 2Avizia Closes Funding Round 2
... Tarsa Therapeutics today announced that the Phase III ORACAL ... treatment of postmenopausal osteoporosis was successfully concluded and yielded ... used to support a New Drug Application (NDA) submission ... the fourth quarter of 2011, based on the study ...
... YORK, March 24, 2011 Reportlinker.com announces that ... its catalogue: RNAi Drug ... http://www.reportlinker.com/p0461653/RNAi-Drug-Delivery-Technologies-and-Global-Markets.html THIS ... to how the RNAi (ribonucleic acid interference) technologies market ...
Cached Medicine Technology:Tarsa Therapeutics Reports Positive Top-Line Results From Pivotal Phase III ORACAL Trial of its Oral Calcitonin in Treatment of Postmenopausal Osteoporosis 2Tarsa Therapeutics Reports Positive Top-Line Results From Pivotal Phase III ORACAL Trial of its Oral Calcitonin in Treatment of Postmenopausal Osteoporosis 3Tarsa Therapeutics Reports Positive Top-Line Results From Pivotal Phase III ORACAL Trial of its Oral Calcitonin in Treatment of Postmenopausal Osteoporosis 4Reportlinker Adds RNAi Drug Delivery: Technologies and Global Markets 2Reportlinker Adds RNAi Drug Delivery: Technologies and Global Markets 3Reportlinker Adds RNAi Drug Delivery: Technologies and Global Markets 4Reportlinker Adds RNAi Drug Delivery: Technologies and Global Markets 5Reportlinker Adds RNAi Drug Delivery: Technologies and Global Markets 6Reportlinker Adds RNAi Drug Delivery: Technologies and Global Markets 7Reportlinker Adds RNAi Drug Delivery: Technologies and Global Markets 8Reportlinker Adds RNAi Drug Delivery: Technologies and Global Markets 9Reportlinker Adds RNAi Drug Delivery: Technologies and Global Markets 10Reportlinker Adds RNAi Drug Delivery: Technologies and Global Markets 11Reportlinker Adds RNAi Drug Delivery: Technologies and Global Markets 12Reportlinker Adds RNAi Drug Delivery: Technologies and Global Markets 13Reportlinker Adds RNAi Drug Delivery: Technologies and Global Markets 14
(Date:8/19/2014)... 19, 2014 Kars4Kids , a ... announced today its partnership with New York State Senator ... in the Bronx. The giveaway will take place in ... Crotona Park on August 22. , “With a ... believe properly preparing children for school with the necessary ...
(Date:8/19/2014)... (PRWEB) August 20, 2014 Top10BestSEOHosting.com has ... GoDaddy and iPage are the most recommended ... Joomla hosting (including VPS and cloud hosting) at an ... competitively priced products and service with some of the ... free). They give their loyal customers a lot of ...
(Date:8/19/2014)... 2014 Grande Naturals, LLC is ... of the 2014 Independent Cosmetics Manufacturers & Distributors ... place position in “Product Innovation; Product Color Cosmetic” ... also includes a lash enhancement serum, GrandeLINER™. ... technology. , This all-new eyeliner is ...
(Date:8/19/2014)... HealthDay Reporter TUESDAY, ... be added to the list of possible harms related ... treat behavioral symptoms of dementia in older adults, a ... olanzapine (Zyprexa) are approved by the U.S. Food and ... serious mental disorders. They are also frequently used "off-label" ...
(Date:8/19/2014)... York (PRWEB) August 19, 2014 As ... Bernstein Liebhard LLP notes the publication of a new ... may increase the risk of acute kidney injury in ... Ottawa Citizen, the study was conducted by researchers at ... the Institute for Clinical Evaluative Sciences, and looked at ...
Breaking Medicine News(10 mins):Health News:Backpack Giveaway Kars4Kids Partners with New York State Senator Gustavo Rivera to Prepare Bronx Students for New School Year 2Health News:Top10BestSEOHosting.com: Cheap Joomla Hosting Reviews Unveiled 2Health News:GrandeLINER™ Wins Independent Cosmetics Manufacturers & Distributors Award 2Health News:GrandeLINER™ Wins Independent Cosmetics Manufacturers & Distributors Award 3Health News:Certain Antipsychotic Meds Tied to Kidney Problems in Elderly 2Health News:Certain Antipsychotic Meds Tied to Kidney Problems in Elderly 3Health News:As Risperdal Lawsuits Mount, Bernstein Liebhard LLP Notes New Study Linking Atypical Antipsychotic Medications to Kidney Damage in Elderly Patients 2Health News:As Risperdal Lawsuits Mount, Bernstein Liebhard LLP Notes New Study Linking Atypical Antipsychotic Medications to Kidney Damage in Elderly Patients 3Health News:As Risperdal Lawsuits Mount, Bernstein Liebhard LLP Notes New Study Linking Atypical Antipsychotic Medications to Kidney Damage in Elderly Patients 4
... A large proteomics study on the brains of newborn ... in obstetric or pediatric medicine can have profound and ... This study, appearing in the December issue of ... of the developing nervous system and reinforces the use ...
... , , WEST ORANGE, N.J., Dec. ... birthday. This year, to her great joy, she was able to experience ... transplant that has a much shorter recovery time than a traditional transplant, ... , , Katherine, who still lives in ...
... Dr Ben Berkhout, a retrovirologist from the Netherlands, ... Retrovirology Prize. He was honoured for his ... additional important building blocks for many aspects of ... research has extended our insights into the mechanisms ...
... C. Benjamin, MD, FACP, FACEP (E), Executive Director, American Public ... Dec. 11 "At a time when national interest in ... Public Health Association (APHA) applauds President-elect Obama for prioritizing health ... Department of Health and Human Services, as well as the ...
... face infection, bleeding, study finds , , THURSDAY, Dec. 11 ... who,ve had multiple, previous pocket procedures have an increased ... a study that included the 12 largest ICD implanting ... the London Health Sciences Center in Ontario, and colleagues ...
... President and CEO of America,s Health Insurance Plans (AHIP), ... nomination of Senator Tom Daschle to be the next ... Services: , , "The ... Daschle because it signals that the incoming administration intends ...
Cached Medicine News:Health News:The profound effects of numbing agents 2Health News:Centenarian's Vision Restored With New Sutureless Corneal Transplant Technology 2Health News:Multiple ICD Replacements Can Predict Complications 2
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: